Oral immunotherapy for peanut allergy can successfully desensitise patients to high doses of peanut protein, but the protection rapidly declines once treatment stops, a US study has found.

The findings are consistent with a recent systematic review and meta-analysis of peanut allergy oral immunotherapy trials, which found the experimental treatment increased the risk of life-threatening anaphylactic reactions without improving quality of life.